85817-34-1

Basic information

• Product Name: 4-N-BENZYL-2-HYDROXYMETHYLPIPERAZINE
• Synonyms: 4-Benzyl-2-(hydroxymethyl)piperazine;1-Benzyl-3-(hydroxymethyl)piperazine;(4-Benzylpiperazin-2-yl)methanol;B67335;2-Piperazinemethanol, 4-(phenylmethyl)-;4-(phenylMethyl)-2-piperazineMethanol;1-Benzyl-3-(hydroxymethyl)piperazine 2HCl;4-(Benzyl)-2-piperazinemethanol
• CAS NO: 85817-34-1
• Molecular Formula: C₁₂H₁₈N₂O
• Molecular Weight: 206.28
• Product Categories: pharmacetical
• Mol File: 85817-34-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 318.1°C at 760 mmHg
• Flash Point: 146.2°C
• Appearance: /
• Density: 1.083g/cm³
• Vapor Pressure: 0.000154mmHg at 25°C
• Refractive Index: 1.551
• Storage Temp.: 2-8°C(protect from light)
• PKA: 14.97±0.10(Predicted)
• CAS DataBase Reference: 4-N-BENZYL-2-HYDROXYMETHYLPIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-N-BENZYL-2-HYDROXYMETHYLPIPERAZINE(85817-34-1)
• EPA Substance Registry System: 4-N-BENZYL-2-HYDROXYMETHYLPIPERAZINE(85817-34-1)

Safety Data

• Hazardous Substances Data: 85817-34-1(Hazardous Substances Data)

Usage

General Description

4-N-Benzyl-2-hydroxymethylpiperazine is a chemical compound that belongs to the class of piperazine derivatives. It is characterized by a piperazine ring with a benzyl group and a hydroxymethyl substituent at the 4th position. 4-N-BENZYL-2-HYDROXYMETHYLPIPERAZINE has been investigated for its potential pharmaceutical properties, including its use as a building block in the synthesis of various bioactive molecules. It has also been studied for its potential antiviral and anticancer activities. Additionally, 4-N-Benzyl-2-hydroxymethylpiperazine has been evaluated for its role as a ligand in coordination chemistry and as a potential agent for the treatment of neurological disorders.

InChI:InChI=1/C12H18N2O/c15-10-12-9-14(7-6-13-12)8-11-4-2-1-3-5-11/h1-5,12-13,15H,6-10H2

Upstream product

• 149648-71-5 ethyl 3-oxo-4-(phenylmethyl)-2-piperazinecarboxylate 
• 149648-70-4 ethyl 3-oxo-1,4-bis(phenylmethyl)-2-piperazinecarboxylate 
• 140-28-3 N,N'-Dibenzylethylenediamine 
• 181955-94-2 4-benzylpiperazine-2-carboxylic acid methyl ester 
• 584-08-7 potassium carbonate 
• 7757-82-6 sodium sulfate 
• 936553-15-0 tert-butyl 4-benzyl-2-(hydroxymethyl)piperazine-1-carboxylate 

Downstream Products

• 126766-44-7 1-<(3,4-dichlorophenyl)acetyl>-4-(phenylmethyl)-2-piperazinemethanol 
• 122323-87-9 2-piperazinemethanol dihydrochloride 
• 936553-19-4 2-[4-benzyl-2-(hydroxymethyl)piperazin-1-yl]-6-nitroquinoline 
• 936553-15-0 tert-butyl 4-benzyl-2-(hydroxymethyl)piperazine-1-carboxylate 
• 936553-20-7 2-[4-benzyl-2-(ethoxymethyl)piperazin-1-yl]-6-nitroquinoline 
• 936553-21-8 2-[4-benzyl-2-(propoxymethyl)piperazin-1-yl]-6-nitroquinoline 
• 936553-22-9 2-[4-benzyl-2-(butoxymethyl)piperazin-1-yl]-6-nitroquinoline 
• 936553-16-1 7-benzylhexahydrooxazolo[3,4-a]pyrazin-3-one 
• 936553-17-2 4-benzyl-2-(methoxymethyl)-1-tert-butoxycarbonylpiperazine 
• 85817-36-3 1-benzyl-3-(methoxymethyl)piperazine 
• 936553-18-3 2-[4-benzyl-2-(methoxymethyl)piperazin-1-yl]-6-nitroquinoline 
• 126766-45-8 1-<(3,4-dichlorophenyl)acetyl>-4-(phenylmethyl)-2-piperazinecarboxaldehyde 
• 133407-23-5 methyl 4-[(3,4-dichlorophenyl)acetyl]-3-[(3-hydroxy-1-pyrrolidinyl)-methyl]-1-piperazinecarboxylate 
• 133407-33-7 1-<(3,4-dichlorophenyl)acetyl>-4-(phenylmethyl)-2-<(3-hydroxy-1-pyrrolidinyl)methyl>piperazine 

Relevant articles and documents

Discovery of novel leukotriene A4 hydrolase inhibitors based on piperidine and piperazine scaffolds

Novel piperidine and piperazine derivatives have been designed and tested as inhibitors of LTA4 hydrolase (LTA4H). Most potent compounds showed good potency in both enzymatic and functional human whole blood assay. Crystallography studies further confirmed observed structure-activity relationship and LTA4H binding mode for analogs from the piperidine series.

Substituted 1,4-piperazine-heteroaryl derivatives as 5-HT1D receptor agonists

A class of 1,4-disubstituted piperazine derivatives, further substituted on one of the carbon atoms of the piperazine ring, are selective agonists of 5-HT1 -like receptors, being potent agonists of the human 5-HT1Dα receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT1Dα receptor subtype relative to the 5-HT1Dβ subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, while eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.